Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 48Multiple Myeloma 39Lymphoma, Large B-Cell, Diffuse 38Burkitt Lymphoma 34Lymphoma 31Leukemia, Myeloid, Acute 31Lymphoma, Non-Hodgkin 29Recurrence 27Breast Neoplasms 27Neoplasms 23Lymphoma, B-Cell 23Myelodysplastic Syndromes 22Leukemia, Lymphocytic, Chronic, B-Cell 22Lymphoma, Follicular 20Hodgkin Disease 18Triple Negative Breast Neoplasms 17Melanoma 17Leukemia 17Ovarian Neoplasms 16Hematologic Neoplasms 15Neuroblastoma 14Lymphoma, Mantle-Cell 13Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 12Pancreatic Neoplasms 12Leukemia, Myelogenous, Chronic, BCR-ABL Positive 12Leukemia, Biphenotypic, Acute 11Neoplasm Metastasis 10Lymphoma, B-Cell, Marginal Zone 10Leukemia, Myelomonocytic, Chronic 10Sarcoma 9

Interventions

prednylidene 1etoposide phosphate 1deltacortene 1Vincristine 1Vinblastine 1Specimen Handling 1Procarbazine 1Prednisone 1Prednisolone 1Nivolumab 1Methylprednisolone 1Magnetic Resonance Spectroscopy 1Fluorodeoxyglucose F18 1Etoposide 1Doxorubicin 1Dacarbazine 1Cyclophosphamide 1Brentuximab Vedotin 1Bleomycin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 × Cyclophosphamide × 90 days × Clear all
NCT05675410 2026-06-03

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

National Cancer Institute (NCI)

Phase 3 Recruiting
1,875 enrolled
Lymphoid

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡